Endothelial progenitor cells and coronary artery disease:Current concepts and future research directions  

作　　者：Sen-Tong Xiao Chun-Yan Kuang 

机构地区：[1]Department of Cardiovascular Diseases,People’s Hospital Affiliated to Guizhou Medical University,Guiyang 550003,Guizhou Province,China [2]Kuang,Department of Cardiovascular Diseases,Guizhou Provincial People's Hospital,Guiyang 550003,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2021年第30期8953-8966,共14页世界临床病例杂志

基　　金：Supported by the Guizhou Science and Technology Department,No.Qian-Ke-He[2018]1097;the National Natural Science Foundation of China,No.81560056;Program for Training Outstanding Young Scientific and Technological Talents of Guizhou Province,No.Qian Kehe Platform Talents[2019]5662;Program for the Scientific Activities of Selected Returned Overseas Professionals in Guizhou Province,No.Grant Qian-Ren[2018]0003;Scientific and Technological Platform and Talent Team Project of Guizhou Province,No.Qian Kehe Platform Talents[2017]5405.

摘　　要：Vascular injury is a frequent pathology in coronary artery disease.To repair the vasculature,scientists have found that endothelial progenitor cells(EPCs)have excellent properties associated with angiogenesis.Over time,research on EPCs has made encouraging progress regardless of pathology or clinical technology.This review focuses on the origins and cell markers of EPCs,and the connection between EPCs and coronary artery disease.In addition,we summarized various studies of EPC-capturing stents and EPC infusion therapy,and aim to learn from past technology to predict the future.

关 键 词：Endothelial progenitor cells Coronary disease Endothelial progenitor-cell capture stents Endothelial progenitor-cell infusion Clinical application 

分 类 号：R543.3[医药卫生—心血管疾病]